Semaglutide led to improved health-related quality of life compared to placebo
Overall, although the overall absolute risk increase is small (27 cases per 10,000 persons treated per year), clinical practitioners should nevertheless take into account the potential risk of gallbladder or biliary diseases associated with GLP-1RAs, especially when used at higher doses, for longer durations, and for weight loss, and in case the patient has a history of lithiasis [64]
A patient on maximum-dose semaglutide (2.4 mg weekly) does not typically start tirzepatide at 15 mg
Lipodystrophy Long-term use of insulin, including TOUJEO, can cause lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) in some patients and may affect insulin absorption [see DOSAGE AND ADMINISTRATION ]
ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry
"S-100 protein as a marker for melanocytic and other tumours"